Mylan receives a $106.7 million verdict against GlaxoSmithKline

Share with others:

Print Email Read Later

Cecil-based generic drug company Mylan Inc. today said a federal New Jersey court has returned a $106.7 million verdict for Mylan in its breach of contract lawsuit against GlaxoSmithKline.

The suit targeted Glaxo’s Paroxetine Hydrochloride Extended-release Tablets, which Mylan said violated 2007 agreements in which Mylan acquired intellectual property rights from Glaxo.

Mylan launched its generic form of the tablets in 2008.

Steve Twedt: or 412-263-1963.

Join the conversation:

Commenting policy | How to report abuse
To report inappropriate comments, abuse and/or repeat offenders, please send an email to and include a link to the article and a copy of the comment. Your report will be reviewed in a timely manner. Thank you.
Commenting policy | How to report abuse


Create a free PG account.
Already have an account?